Synonyms: compound 7 [US20210238168A1]
Compound class:
Synthetic organic
Comment: The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. It is one of the examples claimed in Incyte's JAK inhibitor patent US20210238168A1 [1], which indicates selectivity for JAK1. Information on Incyte's pipeline page suggests that povorcitinib may be their JAK1 inhibitor clinical lead INCB54707, however as of July 2024 there has been no formal name-to-structure disclosure. Clinical trial NCT05936567 refers to the pponsor's internal study number INCB54707-207 which indirectly confirms prediction of the povorcitinib>INCB54707 association.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Povorcitinib (example 7) is >10-fold selective for JAK1 over JAK2 in vitro [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|